Last reviewed · How we verify
Pegylated Recombinant Human G-CSF — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Pegylated Recombinant Human G-CSF (Pegylated Recombinant Human G-CSF) — Jiangsu T-Mab Biopharma Co.,Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pegylated Recombinant Human G-CSF TARGET | Pegylated Recombinant Human G-CSF | Jiangsu T-Mab Biopharma Co.,Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pegylated Recombinant Human G-CSF CI watch — RSS
- Pegylated Recombinant Human G-CSF CI watch — Atom
- Pegylated Recombinant Human G-CSF CI watch — JSON
- Pegylated Recombinant Human G-CSF alone — RSS
Cite this brief
Drug Landscape (2026). Pegylated Recombinant Human G-CSF — Competitive Intelligence Brief. https://druglandscape.com/ci/pegylated-recombinant-human-g-csf. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab